These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34157503)

  • 1. Generating an iPSC line (with isogenic control) from the PBMCs of an ACTA1 (p.Gly148Asp) nemaline myopathy patient.
    Houweling PJ; Coles CA; Tiong CF; Nielsen B; Graham A; McDonald P; Suter A; Piers AT; Forbes R; Ryan MM; Howden SE; Lamandé SR; North KN
    Stem Cell Res; 2021 Jul; 54():102429. PubMed ID: 34157503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of two isogenic induced pluripotent stem cell lines from a 4-month-old severe nemaline myopathy patient with a heterozygous dominant c.553C > A (p.Arg183Ser) variant in the ACTA1 gene.
    Clayton JS; Scriba CK; Romero NB; Malfatti E; Saker S; Larmonier T; Nowak KJ; Ravenscroft G; Laing NG; Taylor RL
    Stem Cell Res; 2021 May; 53():102273. PubMed ID: 33740643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR/Cas9 editing to generate a heterozygous COL2A1 p.G1170S human chondrodysplasia iPSC line, MCRIi019-A-2, in a control iPSC line, MCRIi019-A.
    Kung LHW; Sampurno L; Yammine KM; Graham A; McDonald P; Bateman JF; Shoulders MD; Lamandé SR
    Stem Cell Res; 2020 Oct; 48():101962. PubMed ID: 33002832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACTA1 H40Y mutant iPSC-derived skeletal myocytes display mitochondrial defects in an in vitro model of nemaline myopathy.
    Gartz M; Haberman M; Sutton J; Slick RA; Luttrell SM; Mack DL; Lawlor MW
    Exp Cell Res; 2023 Mar; 424(2):113507. PubMed ID: 36796746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of two isogenic induced pluripotent stem cell lines from a 10-year-old typical nemaline myopathy patient with a heterozygous dominant c.541G>A (p.Asp179Asn) pathogenic variant in the ACTA1 gene.
    Clayton JS; Scriba CK; Romero NB; Malfatti E; Saker S; Larmonier T; Nowak KJ; Ravenscroft G; Laing NG; Taylor RL
    Stem Cell Res; 2021 Aug; 55():102482. PubMed ID: 34388489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of an induced pluripotent stem cell line from a patient with global development delay carrying DYRK1A mutation (c.1730T>A) and a gene correction isogenic iPSC line.
    Ma L; Wu Z; Tang Q; Ji X; Mei Y; Peng T; Xu Q; Zhou W; Xiong M
    Stem Cell Res; 2021 May; 53():102305. PubMed ID: 33813175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integration-free iPSC line (SDQLCHi017-A) derived from a patient with nemaline myopathy-2 disease carrying compound heterozygote mutations in NEB gene.
    Ma Y; Zhang H; Li X; Yang X; Li Y; Guan J; Lv Y; Gai Z; Liu Y
    Stem Cell Res; 2020 Mar; 43():101729. PubMed ID: 32062132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of an induced pluripotent stem cell line from a 3-month-old nemaline myopathy patient with a heterozygous dominant c.515C > A (p.Ala172Glu) variant in the ACTA1 gene.
    Clayton JS; Suleski I; Vo C; Smith R; Scriba CK; Saker S; Larmonier T; Malfatti E; Romero NB; Houweling PJ; Nowak KJ; Ravenscroft G; Laing NG; Taylor RL
    Stem Cell Res; 2022 Aug; 63():102829. PubMed ID: 35728439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of two isogenic induced pluripotent stem cell lines from a 1-month-old nemaline myopathy patient harbouring a homozygous recessive c.121C > T (p.Arg39Ter) variant in the ACTA1 gene.
    Suleski IS; Smith R; Vo C; Scriba CK; Saker S; Larmonier T; Malfatti E; Romero NB; Houweling PJ; Nowak KJ; Laing NG; Taylor RL; Clayton JS
    Stem Cell Res; 2022 Aug; 63():102830. PubMed ID: 35728440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of a human induced pluripotent stem cell line (SDQLCHi004-A) from a patient with nemaline myopathy-4 disease carrying heterozygous mutation in TPM2 gene.
    Ma Y; Zhang H; Yang X; Li Y; Guan J; Lv Y; Li H; Liu Y; Gai Z
    Stem Cell Res; 2019 Oct; 40():101559. PubMed ID: 31526942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9 gene editing of a SOX9 reporter human iPSC line to produce two TRPV4 patient heterozygous missense mutant iPSC lines, MCRIi001-A-3 (TRPV4 p.F273L) and MCRIi001-A-4 (TRPV4 p.P799L).
    Nur Patria Y; Stenta T; Lilianty J; Rowley L; Stanley EG; Elefanty AG; Bateman JF; Lamandé SR
    Stem Cell Res; 2020 Oct; 48():101942. PubMed ID: 32771907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction of Hirschsprung-Associated Mutations in Human Induced Pluripotent Stem Cells Via Clustered Regularly Interspaced Short Palindromic Repeats/Cas9, Restores Neural Crest Cell Function.
    Lai FP; Lau ST; Wong JK; Gui H; Wang RX; Zhou T; Lai WH; Tse HF; Tam PK; Garcia-Barcelo MM; Ngan ES
    Gastroenterology; 2017 Jul; 153(1):139-153.e8. PubMed ID: 28342760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of a heterozygous COL2A1 (p.R989C) spondyloepiphyseal dysplasia congenita mutation iPSC line, MCRIi001-B, using CRISPR/Cas9 gene editing.
    Lilianty J; Nur Patria Y; Stanley EG; Elefanty AG; Bateman JF; Lamandé SR
    Stem Cell Res; 2020 May; 45():101843. PubMed ID: 32446218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of a heterozygous COL1A1 (c.3969_3970insT) osteogenesis imperfecta mutation human iPSC line, MCRIi001-A-1, using CRISPR/Cas9 editing.
    Hosseini Far H; Patria YN; Motazedian A; Elefanty AG; Stanley EG; Lamandé SR; Bateman JF
    Stem Cell Res; 2019 May; 37():101449. PubMed ID: 31075690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of a gene corrected human isogenic iPSC line (CPGHi002-A-1) from a DDOD patient with heterozygous c.1516 C>T mutation in the ATP6V1B2 gene.
    Gao X; Qiu SW; Wang WQ; Kang DY; Su N; Dai P; Yuan YY
    Stem Cell Res; 2021 May; 53():102271. PubMed ID: 33714068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of a gene corrected human isogenic IBMS-iPSC-014-C from polycystic-kidney-disease induced pluripotent stem cell line using CRISPR/Cas9.
    Liu CL; Huang CY; Chen HC; Lu HE; Hsieh PCH; Lee JJ
    Stem Cell Res; 2020 May; 45():101784. PubMed ID: 32361310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful correction of factor V deficiency of patient-derived iPSCs by CRISPR/Cas9-mediated gene editing.
    Nakamura T; Morishige S; Ozawa H; Kuboyama K; Yamasaki Y; Oya S; Yamaguchi M; Aoyama K; Seki R; Mouri F; Osaki K; Okamura T; Mizuno S; Nagafuji K
    Haemophilia; 2020 Sep; 26(5):826-833. PubMed ID: 32700411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of a heterozygous COL2A1 (p.G1113C) hypochondrogenesis mutation iPSC line, MCRIi019-A-7, using CRISPR/Cas9 gene editing.
    Lilianty J; Bateman JF; Lamandé SR
    Stem Cell Res; 2021 Oct; 56():102515. PubMed ID: 34543885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of simultaneous reprogramming and gene correction to generate an osteogenesis imperfecta patient COL1A1 c. 3936 G>T iPSC line and an isogenic control iPSC line.
    Howden S; Hosseini Far H; Motazedian A; Elefanty AG; Stanley EG; Lamandé SR; Bateman JF
    Stem Cell Res; 2019 Jul; 38():101453. PubMed ID: 31082677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of an induced pluripotent stem cell (iPSC) line (INNDSUi004-A) from a patient with Congenital Nemaline Myopathy.
    Wang Y; Liu W; Yang Y; Wang Y; Tang Y; Zhan Z; Sun X; Jiao Y; Shan D; Zhang R; Wang D; Sun P; Sun X; Yan C; Liu F
    Stem Cell Res; 2024 Jun; 77():103435. PubMed ID: 38733812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.